Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

Benalish Jun. 9 at 11:31 PM

$OMER

0 · Reply

UnrealMachine Jun. 9 at 9:05 PM

$OMER big funds won’t typically buy a first of a kind drug at launch they will wait for 3 quarters of sales data to make some low-IQ projections and then initiate coverage and start buying. No one understands or covers this space. It’ll only get attention after a clear transition to a successful commercial phase. May be why Greg keeps emphasizing the breakeven point. Big funds don’t like buying companies losing money.

2 · Reply

RandomInvestor777 Jun. 9 at 9:01 PM

$OMER Anyone noticed they haven't replaced the two chiefs that left? weird

1 · Reply

LeaLeb Jun. 9 at 8:14 PM

$OMER Bullish close.

0 · Reply

h8ster Jun. 9 at 7:55 PM

$OMER 3 more weeks for J-Code activation for YARTEMLEA. Major de-risking event that will likely result in institutional buying.

1 · Reply

RandomInvestor777 Jun. 9 at 7:04 PM

$OMER probably the biggest catalyst is Zaltenibart ph3 here. could push this 100%+ up with further 20-40% up over the weeks or 30% down (in the short term) with slow recovery

3 · Reply

RandomInvestor777 Jun. 9 at 6:16 PM

$OMER 2.8 billion market cap = $40....

2 · Reply

WinstonWolfff Jun. 9 at 6:01 PM

$OMER

3 · Reply

RandomInvestor777 Jun. 9 at 5:46 PM

$OMER NVO should just buy it for 2.5b at this point

2 · Reply

Benalish Jun. 9 at 5:09 PM

$OMER Red is market noise - green will be hype from EMA soon

0 · Reply

Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 27 days ago

Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 27 days ago

Omeros Quarterly report: Q1 2026

2026-05-13T20:27:08.000Z - 27 days ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 27 days ago

Omeros Corporation Reports First Quarter 2026 Financial Results

May 11, 2026, 4:02 PM EDT - 4 weeks ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 5 weeks ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Omeros Proxy statement: Proxy filing

2026-04-16T14:14:18.000Z - 7 weeks ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 7 weeks ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 2 months ago

Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 2 months ago

Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 2 months ago

Omeros Annual report: Q4 2025

2026-03-31T20:05:48.000Z - 2 months ago

Omeros reports Q4 EPS $1.22, consensus 36c

Mar 31, 2026, 4:02 PM EDT - 2 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 2 months ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 2 months ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T14:15:38.000Z - 4 months ago

Omeros announces completion of nonhuman primates OncotoX-AML study

Feb 17, 2026, 8:45 AM EST - 4 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

2026-01-27T14:20:24.000Z - 4 months ago

Omeros announces first commercial sales of Yartemlea

Jan 27, 2026, 9:00 AM EST - 4 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

2026-01-08T11:11:35.000Z - 5 months ago

Omeros price target raised to $40 from $20 at H.C. Wainwright

Jan 7, 2026, 6:50 PM EST - 5 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 5 months ago

Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 5 months ago

Omeros Press release: FDA Announcement

Dec 26, 2025, 6:36 PM EST - 5 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

2025-12-24T15:55:07.000Z - 5 months ago

D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating

2025-12-24T15:30:10.000Z - 5 months ago

H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value

2025-12-24T15:15:15.000Z - 5 months ago

Omeros trading resumes

2025-12-24T15:10:19.000Z - 5 months ago

Omeros trading halted, volatility trading pause

2025-12-24T15:10:08.000Z - 5 months ago

Omeros up 100% at $17.55 upon resumption of trading

2025-12-24T14:40:42.000Z - 5 months ago

Omeros to resume trading at 9:50 am ET

2025-12-24T14:05:07.000Z - 5 months ago

Omeros announces FDA approved YARTEMLE for treatment of TA-TMA

Dec 24, 2025, 9:05 AM EST - 5 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 5 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

2025-12-24T11:45:14.000Z - 5 months ago

Omeros trading halted, news pending

Dec 1, 2025, 8:30 AM EST - 6 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 7 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 7 months ago

Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 7 months ago

Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:11 PM EST - 7 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 7 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 16, 2025, 8:30 AM EDT - 8 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 8 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 8 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 8 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 8 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 10 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 10 months ago

Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 10 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 10 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 1 year ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 1 year ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Quarterly report: Q3 2024

Nov 13, 2024, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 1 year ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2024

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 2 years ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Jun 3, 2024, 9:00 AM EDT - 2 years ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

May 15, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings Call Transcript: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Omeros Quarterly report: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings release: Q1 2024

May 15, 2024, 4:02 PM EDT - 2 years ago

Omeros Corporation Reports First Quarter 2024 Financial Results

Benalish Jun. 9 at 11:31 PM

$OMER

0 · Reply

UnrealMachine Jun. 9 at 9:05 PM

2 · Reply

RandomInvestor777 Jun. 9 at 9:01 PM

$OMER Anyone noticed they haven't replaced the two chiefs that left? weird

1 · Reply

LeaLeb Jun. 9 at 8:14 PM

$OMER Bullish close.

0 · Reply

h8ster Jun. 9 at 7:55 PM

$OMER 3 more weeks for J-Code activation for YARTEMLEA. Major de-risking event that will likely result in institutional buying.

1 · Reply

RandomInvestor777 Jun. 9 at 7:04 PM

$OMER probably the biggest catalyst is Zaltenibart ph3 here. could push this 100%+ up with further 20-40% up over the weeks or 30% down (in the short term) with slow recovery

3 · Reply

RandomInvestor777 Jun. 9 at 6:16 PM

$OMER 2.8 billion market cap = $40....

2 · Reply

WinstonWolfff Jun. 9 at 6:01 PM

$OMER

3 · Reply

RandomInvestor777 Jun. 9 at 5:46 PM

$OMER NVO should just buy it for 2.5b at this point

2 · Reply

Benalish Jun. 9 at 5:09 PM

$OMER Red is market noise - green will be hype from EMA soon

0 · Reply

kreftslag Jun. 9 at 4:59 PM

$OMER Can someone articulate a justification for Omeros having a $680M market cap at this point?

2 · Reply

LowCountry15 Jun. 9 at 4:29 PM

$OMER (1 of n) Why Now Is the Strongest Case Ever for OMER M&A - A Thread The case for a full acquisition of Omeros (OMER) by Novo Nordisk has never been stronger. Every major variable that drives M&A has moved decisively in favor of a deal right now. Here are the specific factors that have meaningfully shifted the needle: Pre-existing deep relationship (biggest factor): Novo has had nearly a full year of intimate, hands-on knowledge of Omeros through the extensive zaltenibart (OMS906) due-diligence process. This dramatically lowers execution risk and shortens the time required to negotiate and close.

9 · Reply

MinnieSteve3 Jun. 9 at 4:10 PM

$OMER Looking forward to listening to Greg at the ASM on June 18th. I'm certain that no one feels worse than he does with a sub-$10 share price. Too bad the CHMP meeting is the following week

0 · Reply

Jon447788 Jun. 9 at 3:46 PM

$OMER nice leg is forming, it should see $6 by the end of this week. Don’t get fooled with bullish posts

0 · Reply

opmankc Jun. 9 at 2:43 PM

$OMER the wait is almost over. bought more!

0 · Reply

BioBomber Jun. 9 at 2:09 PM

$OMER 6 months ago today we were at $11.50, Narso was approved yet. Hmmm 🤔

2 · Reply

capntrps Jun. 9 at 1:51 PM

$OMER does omer do any pipeline stuffing with its business model that would cause sales to level in the next Q, or will they see a ramp based on actual demand? Important distinctions for setting expectations. I think they generally sell just on need, but i am no expert on the matter. Who knows...

0 · Reply

uptech Jun. 9 at 1:36 PM

$OMER Added yet again. Liking these 9 handle entries yesterday and today.

0 · Reply

Phase3 Jun. 9 at 1:15 PM

$OMER Ok so the stock is down and Greg is taking heat, but he's been executing lately so I've been adding. 17m to 20m would be a solid q2. Optimistic and ....

2 · Reply

muti21 Jun. 9 at 6:40 AM

$OMER fells like new updates are coming

0 · Reply

costrexx Jun. 9 at 12:06 AM

$OMER a couple more jobs have been posted. https://effy.fa.us6.oraclecloud.com/hcmUI/CandidateExperience/en/sites/CX/jobs?mode=location

0 · Reply

vu_jade Jun. 8 at 8:00 PM

Under $10 back in $OMER Overdone

0 · Reply

Market Cap	712.89M
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	4.49
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-2.16

Volume	1,544,600
Avg Vol	1,508,950
Day's Range	N/A - N/A
Shares Out	72.38M
Stochastic %K	25%
Beta	2.52
Analysts	Strong Sell
Price Target	$47.50